Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. It is crucial for clinicians to exercise independent medical judgment and to consult official guidelines, recent literature, and specialists when making patient care decisions. The information provided herein is subject to change as new evidence emerges.

---

Varicella

Overview

• Definition: Varicella, commonly known as chickenpox, is a highly contagious acute viral infection caused by the Varicella-Zoster Virus (VZV), a human alpha-herpesvirus. It is characterized by a distinctive pruritic, vesicular rash that typically evolves through maculopapular, vesicular, pustular, and crusting stages.
• Epidemiology:
  • Global Incidence: Before widespread vaccination, varicella was a universal childhood disease, with over 90% of individuals infected by age 15. The introduction of the varicella vaccine has dramatically reduced its incidence globally.
  • Seasonality: In temperate climates, varicella typically exhibits a winter-spring seasonality.
  • Transmission: Primarily airborne via respiratory droplets (coughing, sneezing) and direct contact with vesicular fluid from skin lesions. Less commonly, transmission can occur through contaminated objects.
  • Contagious Period: Approximately 1-2 days before rash onset until all lesions have crusted over (typically 5-7 days after rash onset).
  • Impact of Vaccination: In countries with high vaccine coverage (e.g., USA), incidence has decreased by >90%, hospitalizations by >80%, and deaths by >95%. The epidemiology has shifted, with a higher proportion of cases now occurring in older children, adolescents, and adults (often breakthrough infections).
• Classification: Varicella refers specifically to the primary infection with VZV. Reactivation of latent VZV causes herpes zoster (shingles).

Pathophysiology

• Mechanism:
  1. Infection: VZV is typically acquired via inhalation of airborne droplets or direct contact with vesicular fluid.
  2. Primary Replication: The virus initially replicates in the nasopharynx and regional lymph nodes.
  3. Primary Viremia: After approximately 4-6 days, VZV enters the bloodstream (primary viremia), disseminating to the reticuloendothelial system (e.g., liver, spleen).
  4. Secondary Replication & Viremia: Further viral replication occurs, leading to a more substantial secondary viremia (around days 9-14 post-exposure).
  5. Skin Manifestations: VZV then disseminates to the skin, causing the characteristic vesicular rash. Infected cells exhibit intranuclear inclusions (Cowdry type A bodies).
  6. Immune Response: The host immune system mounts a cellular and humoral response, clearing the viremia and skin lesions.
  7. Latency: Crucially, VZV establishes latency in sensory nerve ganglia (e.g., dorsal root ganglia) following primary infection. This latent virus can reactivate decades later to cause herpes zoster.
• Risk Factors:
  • Lack of prior varicella infection or vaccination.
  • Exposure to an individual with active varicella or herpes zoster.
  • Immunocompromised status (e.g., HIV/AIDS, chemotherapy, organ transplant recipients, high-dose corticosteroid use). These individuals are at risk for more severe, disseminated disease.
  • Age: Adults and adolescents often experience more severe disease and a higher risk of complications compared to healthy children.
  • Pregnancy: Susceptible pregnant women are at higher risk of severe disease and can transmit the virus to the fetus/neonate.
  • Neonates: Especially if maternal varicella occurs shortly before or after birth.
• Protective Factors:
  • Prior Natural Infection: Generally confers lifelong immunity.
  • Varicella Vaccine: Highly effective in preventing varicella or significantly modifying its course (breakthrough infection). Two doses provide superior protection compared to one.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Rash: The hallmark of varicella. It typically begins as erythematous macules, progressing rapidly (hours) to papules, then to characteristic clear, fluid-filled vesicles ("dewdrop on a rose petal" appearance), which become cloudy and then rupture, forming crusted lesions. Lesions appear in crops, so multiple stages of lesions (macules, papules, vesicles, crusts) are present simultaneously (polymorphous rash).
  • Pruritus: Intense itching is nearly universal.
  • Fever: Low-grade to moderate fever (typically 38-39°C) is common, especially in adults and older children.
  • Malaise: General feeling of discomfort, body aches.
  • Anorexia: Loss of appetite.
• Early Signs:
  • Prodrome: In adults, adolescents, and sometimes older children, a prodromal phase of 1-2 days may precede the rash, consisting of fever, malaise, headache, and anorexia. In young children, the rash is often the first sign.
  • Rash onset: Usually starts on the trunk and face, then spreads centrifugally to the extremities. Lesions may also appear on mucous membranes (mouth, pharynx, conjunctiva, genital areas), which can be painful.
• Advanced Signs:
  • Extensive Rash: In severe cases, particularly in immunocompromised individuals, the rash can be very extensive, confluent, and may involve internal organs.
  • Complications: Signs of complications include persistent high fever, severe headache, neck stiffness, altered mental status, seizures, respiratory distress, severe abdominal pain, hemorrhagic lesions, or signs of bacterial superinfection (erythema, pain, purulent discharge from lesions).
• Atypical Presentations:
  • Modified Varicella (Breakthrough Varicella): Occurs in vaccinated individuals. Typically presents with fewer lesions (<50), often maculopapular rather than vesicular, milder systemic symptoms, and shorter duration. Still contagious.
  • Congenital Varicella Syndrome (CVS): If maternal infection occurs during the first 20 weeks of gestation. Characterized by skin scarring, limb hypoplasia, microcephaly, chorioretinitis, cataracts, microphthalmia, and neurological deficits.
  • Perinatal Varicella: If maternal infection occurs 5 days before to 2 days after delivery. High risk of severe, disseminated neonatal varicella due to lack of protective maternal antibodies.
  • Hemorrhagic Varicella: Rare but severe form, typically in immunocompromised individuals, characterized by bleeding into vesicles and purpura.
  • Bullous Varicella: Characterized by large, fluid-filled bullae, often associated with bacterial superinfection (e.g., Staphylococcus aureus).
  • Atypical Hosts: Immunocompromised individuals often have prolonged illness, higher viral load, and increased risk of visceral dissemination (pneumonia, encephalitis, hepatitis).

Physical Examination

• Inspection:
  • Skin: Polymorphous rash with lesions in various stages of development (macules, papules, vesicles, pustules, crusts) simultaneously. Usually begins on the trunk and face, then spreads. Vesicles are typically small (2-4 mm), superficial, and surrounded by an erythematous halo.
  • Mucous Membranes: Lesions may be present in the oral cavity (enanthema), pharynx, conjunctiva, and genitalia. Oral lesions often ulcerate.
• Palpation:
  • Lymph Nodes: Mild to moderate regional lymphadenopathy (e.g., posterior cervical, occipital) may be palpable.
  • Skin Lesions: Vesicles are typically non-tender unless secondarily infected.
• Special Tests: None specific for physical examination diagnosis. The diagnosis is primarily clinical based on the characteristic rash.

Diagnostic Approach

History Taking

• Key Questions:
  • Exposure History: Has the patient been exposed to anyone with chickenpox or shingles in the past 2-3 weeks? (Incubation period typically 10-21 days, average 14-16 days).
  • Vaccination Status: Has the patient received varicella vaccine? If so, how many doses and when? (To assess for breakthrough infection or susceptibility).
  • Prior Infection: History of previous chickenpox? (To assess for immunity, though rare second infections can occur).
  • Rash Characteristics: Onset, location, progression (e.g., started as spots, became blisters, then crusted), associated pruritus.
  • Systemic Symptoms: Fever, malaise, headache, anorexia, muscle aches, respiratory symptoms (cough, shortness of breath), neurological symptoms (altered mental status, seizures, ataxia).
  • Immunocompromise: Any underlying conditions or medications (e.g., cancer, HIV, organ transplant, corticosteroids, biologic agents) that suppress the immune system?
  • Pregnancy Status: For females of childbearing age, is there a possibility of pregnancy?
  • Aspirin Use: Is the patient taking aspirin or salicylate-containing products? (Crucial to avoid due to Reye's syndrome risk).
• Red Flags:
  • Severe Systemic Symptoms: High fever (>39.5°C), persistent vomiting, lethargy, significant malaise.
  • Neurological Signs: Severe headache, neck stiffness, photophobia, altered mental status, seizures, ataxia, nystagmus. (Suggests encephalitis, meningitis, or cerebellar ataxia).
  • Respiratory Distress: Cough, dyspnea, tachypnea, chest pain. (Suggests varicella pneumonia).
  • Hemorrhagic Lesions: Vesicles with blood, purpura, petechiae, or excessive bleeding.
  • Signs of Sepsis: Hypotension, tachycardia, poor perfusion.
  • Extensive or Confluent Rash: Particularly in immunocompromised individuals.
  • Neonatal Varicella: Rash onset in a neonate, especially if maternal varicella occurred around delivery.

Laboratory Tests

• First-Line:
  • Clinical Diagnosis: In most cases of uncomplicated varicella in healthy children, the diagnosis is made clinically based on the characteristic rash and exposure history. Laboratory confirmation is often not necessary.
  • Polymerase Chain Reaction (PCR): If laboratory confirmation is needed (e.g., atypical presentation, immunocompromised patient, forensic purposes), PCR for VZV DNA from vesicular fluid, lesion swabs, or scabs is the preferred first-line confirmatory test. It is highly sensitive and specific.
• Confirmatory:
  • VZV PCR: As above, from vesicular fluid, scabs, or mucosal lesions. For CNS complications, CSF VZV PCR. For pneumonia, BAL fluid PCR.
  • Direct Fluorescent Antibody (DFA) staining: From vesicular fluid or lesion scrapings to detect VZV antigens. Less sensitive than PCR but can provide rapid results.
  • VZV Serology:
    • IgM antibody: Indicates acute or recent infection. May not be positive early in the illness. Can be helpful in diagnosing primary infection in equivocal cases or in adults/pregnant women.
    • IgG antibody: Indicates past infection or vaccination (immunity). Useful for determining immune status in exposed susceptible individuals.
• Monitoring:
  • Routine laboratory monitoring is generally not required for uncomplicated varicella.
  • If complications are suspected:
    • Complete Blood Count (CBC): May show leukocytosis with bacterial superinfection or lymphopenia in severe viral infection.
    • Inflammatory Markers: ESR, CRP if bacterial superinfection or systemic inflammation is suspected.
    • Liver Function Tests (LFTs): If hepatitis is suspected (especially in immunocompromised).
    • Renal Function Tests (RFTs): If acute kidney injury is suspected.
    • CSF Analysis: For suspected CNS complications (elevated protein, pleocytosis, VZV PCR).

Imaging

• Recommended:
  • Chest X-ray (CXR): If varicella pneumonia is suspected (e.g., cough, dyspnea, hypoxia, chest pain), particularly in adults, pregnant women, or immunocompromised individuals. Findings may include diffuse bilateral nodular infiltrates or interstitial pneumonia.
• Advanced:
  • CT or MRI of the Brain: If CNS complications (e.g., encephalitis, cerebellitis, stroke, vasculopathy) are suspected based on neurological signs. May show focal lesions, edema, or vasculitis.
  • Abdominal Ultrasound or CT: If visceral involvement (e.g., hepatitis, pancreatitis) is suspected.

Management

Acute Management

• Immediate:
  • Symptomatic Relief: Focus on alleviating symptoms.
    • Antipyretics: Acetaminophen (paracetamol) for fever. Avoid aspirin/salicylates in children and adolescents due to the risk of Reye's syndrome.
    • Antipruritics: Oral antihistamines (e.g., hydroxyzine, diphenhydramine) to reduce itching and promote sleep. Topical lotions (calamine lotion) or colloidal oatmeal baths can soothe the skin.
  • Hydration: Encourage fluid intake.
  • Infection Control: Isolate the patient to prevent spread (until all lesions are crusted). Avoid contact with susceptible individuals, especially immunocompromised persons, pregnant women, and neonates.
• Stabilization:
  • Antiviral Therapy: Consider for at-risk individuals to reduce severity and duration of illness, and prevent complications. Antivirals are most effective when started within 24-48 hours of rash onset.
    • Indications for Antiviral Therapy (Oral):
      • Healthy adolescents (>12 years old).
      • Adults.
      • Secondary household cases (often more severe).
      • Individuals with chronic cutaneous or pulmonary disorders (e.g., eczema, asthma).
      • Individuals receiving long-term salicylate therapy (risk of Reye's syndrome).
      • Immunocompromised individuals (these usually require IV).
    • Indications for Antiviral Therapy (Intravenous):
      • Immunocompromised individuals of any age.
      • Individuals with severe, complicated varicella (e.g., pneumonia, encephalitis, hemorrhagic varicella, extensive cutaneous lesions).
      • Neonates with perinatal varicella.
      • Pregnant women with severe varicella (e.g., pneumonia).
  • Prevent Secondary Bacterial Infection: Keep nails trimmed, encourage hand hygiene, avoid scratching. Consider topical or oral antibiotics if signs of bacterial superinfection (e.g., impetigo, cellulitis) develop.
• Emergency:
  • Manage life-threatening complications aggressively.
  • Varicella Pneumonia: Respiratory support (oxygen, mechanical ventilation if needed), IV acyclovir.
  • Encephalitis/CNS Complications: IV acyclovir, supportive care, anti-epileptics if seizures occur.
  • Sepsis/Severe Bacterial Superinfection: IV antibiotics, fluid resuscitation, vasopressors as needed.

Chronic Management

Varicella is an acute infection; there is no chronic management in the typical sense. Long-term implications relate to the risk of herpes zoster reactivation.

Treatment Algorithms

• First-Line:
  • Healthy Children (<12 years old): Symptomatic treatment only (acetaminophen, antipruritics). Antiviral therapy is generally not recommended unless there are specific risk factors or severe disease.
  • Healthy Adolescents (≥12 years old) and Adults: Oral antiviral therapy (Acyclovir, Valacyclovir, or Famciclovir) initiated within 24-48 hours of rash onset.
    • Acyclovir: Oral, 800 mg 5 times daily for 5-7 days.
    • Valacyclovir: Oral, 1 gram 3 times daily for 5-7 days. (Prodrug of acyclovir, better bioavailability).
    • Famciclovir: Oral, 500 mg 3 times daily for 5-7 days. (Prodrug of penciclovir).
  • Immunocompromised Individuals (all ages) or Severe Varicella: Intravenous (IV) Acyclovir is the cornerstone of treatment.
    • Acyclovir: IV, 10 mg/kg (or 500 mg/m^2) every 8 hours for 7-10 days, or until no new lesions appear for 48 hours. Adjust for renal function.
• Second-Line:
  • If oral antivirals fail or disease progresses despite oral therapy, transition to IV acyclovir.
  • Consider resistant VZV strains in severely immunocompromised patients with prolonged or progressive disease despite adequate acyclovir therapy.
• Refractory Cases:
  • For suspected acyclovir-resistant VZV (rare, typically in severely immunocompromised patients with prolonged exposure to acyclovir), foscarnet may be considered. Resistance testing should be performed.
  • Rule out other diagnoses or co-infections.
  • Optimize management of underlying immunocompromising conditions.

Complications

• Common:
  • Bacterial Superinfection of Skin Lesions: The most common complication, typically caused by Staphylococcus aureus or Streptococcus pyogenes. Can lead to impetigo, cellulitis, abscesses, or erysipelas.
  • Dehydration: Due to fever, poor fluid intake, and discomfort from oral lesions.
• Serious:
  • Varicella Pneumonia: The most serious complication in adults, pregnant women, and immunocompromised individuals. Can be severe and fatal.
  • Central Nervous System (CNS) Complications:
    • Cerebellar Ataxia: Most common neurological complication in children, usually benign and self-limiting, occurring 1-3 weeks after rash.
    • Encephalitis: More serious, can lead to seizures, altered mental status, and permanent neurological sequelae. More common in adults.
    • Aseptic Meningitis: Less common.
    • VZV Vasculopathy: Rare, can lead to stroke.
  • Reye's Syndrome: A rare but severe complication (encephalopathy with fatty liver degeneration) almost exclusively associated with aspirin use during varicella or other viral infections.
  • Hemorrhagic Varicella: Severe, often fatal, especially in immunocompromised patients.
  • Necrotizing Fasciitis: Rare but life-threatening bacterial superinfection.
  • Other Visceral Complications: Hepatitis, glomerulonephritis, myocarditis, arthritis, osteomyelitis, pancreatitis. These are rare in healthy individuals but more common in immunocompromised hosts.
• Long-term:
  • Herpes Zoster (Shingles): Reactivation of latent VZV from sensory ganglia, leading to a painful dermatomal rash. The risk increases with age and immunocompromise.
  • Post-herpetic Neuralgia: Chronic pain after herpes zoster, more common in older adults. Less common after primary varicella, but can occur after zoster reactivation.
  • Scarring: From deeply infected or scratched lesions.

Prognosis

• Factors:
  • Age: Prognosis is generally excellent in healthy children. Worse in adults, adolescents, and infants, with higher rates of complications and mortality.
  • Immune Status: Immunocompromised individuals (e.g., HIV, malignancy, transplant recipients) have a significantly worse prognosis, with higher rates of severe, disseminated disease and mortality.
  • Presence of Comorbidities: Underlying chronic diseases increase complication risk.
  • Timeliness of Antiviral Therapy: Early initiation of antivirals in at-risk groups improves outcomes.
• Survival:
  • Healthy Children: Mortality rate is extremely low, estimated at less than 1 per 100,000 cases.
  • Adults: Mortality rates are significantly higher, up to 15-30 times higher than in children, primarily due to pneumonia.
  • Immunocompromised Individuals: Mortality rates can be 5-15% or higher, depending on the degree of immunosuppression and type of complication.
• Quality of Life: Most healthy individuals make a full recovery without long-term sequelae. Permanent scarring can occur from severe or scratched lesions. Neurological complications, though rare, can lead to long-term disability.

Prevention

• Primary: Preventing initial occurrence of varicella.
  • Vaccination: The most effective primary prevention strategy.
    • Varicella Vaccine (Live-Attenuated):
      • Routine Childhood Immunization: Two doses are recommended:
        • First dose: 12-15 months of age.
        • Second dose: 4-6 years of age (before school entry).
      • Catch-up Vaccination: All healthy individuals aged 13 years or older without evidence of immunity should receive two doses, administered 4-8 weeks apart.
      • Contraindications: Pregnancy, severe immunosuppression, active untreated tuberculosis, history of severe allergic reaction to vaccine components.
    • Measles, Mumps, Rubella, and Varicella (MMRV) vaccine: Can be used for the first dose in children aged 12 months to 12 years if MMR and varicella vaccines are administered simultaneously.
  • Infection Control: Isolation of infected individuals until all lesions are crusted over (typically 5-7 days from rash onset). Avoid sharing personal items. Respiratory precautions.
• Secondary: Early detection and intervention after exposure to prevent or modify disease.
  • Post-exposure Prophylaxis (PEP):
    • Varicella-Zoster Immune Globulin (VZIG) / VariZIG: Passive immunization providing temporary protection. Recommended for high-risk, susceptible individuals exposed to VZV.
      • Indications:
        • Immunocompromised individuals (e.g., leukemia, HIV, organ transplant, significant corticosteroid use) without evidence of immunity.
        • Susceptible pregnant women.
        • Premature infants (gestational age ≥28 weeks whose mother has no immunity or <28 weeks regardless of maternal immunity).
        • Neonates whose mothers develop varicella from 5 days before to 2 days after delivery.
      • Administration: Must be given as soon as possible after exposure, ideally within 96 hours (up to 10 days in some guidelines), typically 125 units/10 kg body weight (max 625 units) IM.
    • Varicella Vaccine: Can be given as PEP to healthy, susceptible individuals aged ≥12 months if administered within 3-5 days (up to 72 hours is optimal) of exposure. It can prevent or significantly modify the disease. Not recommended for high-risk groups requiring VZIG.
    • Antivirals for PEP: Not routinely recommended for PEP in healthy individuals. May be considered for high-risk exposed individuals (e.g., pregnant women) if VZIG is unavailable or contraindicated, but efficacy as PEP is less established than VZIG/vaccine.
• Tertiary: Preventing complications and long-term sequelae in infected individuals.
  • Prompt Antiviral Therapy: In at-risk groups to reduce disease severity and risk of complications.
  • Management of Complications: Early diagnosis and aggressive treatment of bacterial superinfection, pneumonia, or CNS complications.
  • Herpes Zoster Vaccine (Shingrix): Recommended for adults aged ≥50 years (2 doses, 2-6 months apart) to prevent zoster reactivation, regardless of prior chickenpox or zoster history, or prior Zostavax vaccination. This is to prevent future zoster, not related to acute varicella.

Special Populations

• Pediatric:
  • General: Varicella is typically a mild, self-limiting disease in healthy children.
  • Aspirin Avoidance: Absolute contraindication to aspirin/salicylates due to Reye's syndrome risk.
  • Antivirals: Generally not recommended for healthy children unless specific risk factors (e.g., chronic skin or lung disease, chronic salicylate use, secondary household cases, or severe disease).
• Geriatric:
  • Severity: Varicella tends to be more severe in older adults, with a significantly higher risk of complications, especially pneumonia and death.
  • Management: Antiviral therapy is always recommended for adults with varicella.
  • Prevention: Varicella vaccine is crucial for susceptible older adults. Herpes Zoster vaccine is also vital for this age group given the increased risk of zoster.
• Pregnancy:
  • Maternal Risk: Susceptible pregnant women are at higher risk of severe varicella, especially varicella pneumonia (which has a high mortality rate).
  • Fetal/Neonatal Risk:
    • Congenital Varicella Syndrome (CVS): If maternal infection occurs in the first 20 weeks of gestation (risk highest 8-20 weeks). Can cause severe birth defects (limb hypoplasia, skin scarring, neurological and ocular abnormalities). Risk is low (~0.4-2%).
    • Perinatal Varicella: If maternal rash onset is 5 days before to 2 days after delivery. The neonate acquires the virus but has not received sufficient maternal antibodies, leading to severe disseminated neonatal varicella (mortality up to 30%).
  • Management:
    • PEP: Susceptible pregnant women exposed to VZV should receive VariZIG as soon as possible (ideally within 96 hours).
    • Treatment: If varicella develops, oral acyclovir is typically recommended. For severe disease (e.g., pneumonia), IV acyclovir is indicated.
    • Neonatal: Neonates exposed to maternal varicella in the perinatal period require immediate VariZIG and often IV acyclovir.
  • Vaccination: Varicella vaccine is contraindicated during pregnancy. Women should be screened for immunity prior to pregnancy and vaccinated if susceptible.
• Comorbidities:
  • Immunocompromised Patients: (e.g., HIV, organ transplant, chemotherapy, high-dose systemic corticosteroids). At very high risk for severe, prolonged, disseminated, and life-threatening varicella.
    • Management: IV acyclovir is mandatory and should be initiated immediately upon diagnosis or strong suspicion. High index of suspicion for visceral complications.
    • PEP: VariZIG for exposed susceptible immunocompromised individuals.
  • Chronic Pulmonary Disease (e.g., Asthma, COPD): Higher risk of varicella pneumonia. Antiviral therapy is recommended.
  • Chronic Skin Conditions (e.g., Eczema): Increased risk of bacterial superinfection and more extensive skin involvement. Antiviral therapy is recommended.

Clinical Pearls

• Diagnostic:
  • The key to diagnosis is the polymorphous rash: lesions in various stages (macules, papules, vesicles, crusts) simultaneously. This distinguishes it from other rashes like smallpox (lesions in same stage) or enteroviral rashes.
  • "Dewdrop on a rose petal" is a classic description of the early vesicle.
  • Clinical diagnosis is usually sufficient; laboratory confirmation (PCR) is reserved for atypical cases, immunocompromised patients, or epidemiological purposes.
• Treatment:
  • Timeliness is crucial for antivirals: To be most effective, acyclovir, valacyclovir, or famciclovir must be started within 24-48 hours of rash onset, especially in at-risk groups.
  • Aspirin is contraindicated: Emphasize avoidance of aspirin and salicylate-containing products in children and adolescents with varicella due to the risk of Reye's syndrome.
  • IV Acyclovir for severe cases: Don't hesitate to use IV acyclovir for immunocompromised patients, those with pneumonia, encephalitis, or other severe complications.
• Pitfalls:
  • Underestimating severity in adults/adolescents: Varicella is often more severe in these age groups and carries a higher risk of complications (especially pneumonia) compared to children.
  • Delay in antiviral therapy: Waiting too long to initiate antivirals in at-risk groups negates their benefit.
  • Missing a history of aspirin use: Always ask about medication use in febrile children.
  • Misdiagnosis: Can be confused with other vesicular rashes like herpes simplex, hand-foot-and-mouth disease, insect bites, or impetigo. Consider laboratory confirmation if presentation is atypical.
  • Not considering Varicella-Zoster Immune Globulin (VariZIG) for high-risk exposures: Prompt administration can prevent or modify severe disease.

Recent Updates

• Guidelines: Current ACIP (Advisory Committee on Immunization Practices) guidelines continue to strongly recommend routine 2-dose varicella vaccination for children and susceptible adults.
• Evidence:
  • Ongoing surveillance confirms the significant reduction in varicella incidence, hospitalizations, and deaths due to widespread vaccination.
  • Studies continue to evaluate the efficacy of the 2-dose vaccine regimen against breakthrough infections, showing high effectiveness but recognizing that breakthrough cases can occur, though typically milder.
  • Data on the long-term protection of the vaccine and its impact on the epidemiology of herpes zoster are still evolving.
• Controversies:
  • The optimal management of severe breakthrough varicella infections, especially in specific patient populations, remains an area of clinical discussion.
  • Balancing the public health benefit of widespread vaccination with individual preferences and concerns about vaccine-related adverse events.

Key References

• Guidelines:
  • Centers for Disease Control and Prevention (CDC) - Advisory Committee on Immunization Practices (ACIP): Varicella Vaccine Recommendations. Accessible via CDC website.
  • Infectious Diseases Society of America (IDSA): Clinical Practice Guidelines for the Management of Varicella-Zoster Virus Infections. While specific varicella guidelines might be integrated into broader herpesvirus guidelines, they provide key insights into antiviral use.
  • American Academy of Pediatrics (AAP) - Red Book: Report of the Committee on Infectious Diseases. Comprehensive recommendations for pediatric infections and immunizations.
• Studies:
  • Kuter BJ, et al. Ten year follow-up of the Oka/Merck Varicella Vaccine in healthy children. Arch Pediatr Adolesc Med. 2004;158(12):1135-41. (Landmark study on vaccine efficacy).
  • Salloum R, et al. Varicella incidence and associated complications during 20 years of routine childhood vaccination in the United States. Clin Infect Dis. 2017;64(10):1342-8. (Recent epidemiological data on vaccine impact).
• Reviews:
  • Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9(3):361-81. (Classic comprehensive review of VZV biology and clinical aspects).
  • Pichichero ME, et al. Clinical presentation and management of varicella. UpToDate. (Excellent comprehensive clinical overview, regularly updated).
  • Marin M, et al. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1-40. (Detailed guidelines for prevention).